STOCK TITAN

Monthly information on share capital and company voting rights

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Cellectis (CLLS) has released its monthly update on share capital and voting rights as of August 31, 2024. The company reported a total of 100,093,635 shares in the capital and 88,029,440 voting rights. This information is disclosed in compliance with Article 223-16 of the General Regulation of the French financial markets authority. Cellectis is listed on the Euronext Growth market under the ISIN code FR0010425595.

For investors seeking further information, Cellectis has provided contact details for media and investor relations inquiries. This regular disclosure helps maintain transparency and keeps shareholders informed about the company's capital structure.

Cellectis (CLLS) ha pubblicato il suo aggiornamento mensile sul capitale sociale e sui diritti di voto al 31 agosto 2024. L'azienda ha riportato un totale di 100.093.635 azioni nel capitale e 88.029.440 diritti di voto. Queste informazioni sono divulgate in conformità con l'Articolo 223-16 del Regolamento Generale dell'autorità di mercato finanziario francese. Cellectis è quotata sul mercato Euronext Growth con il codice ISIN FR0010425595.

Per gli investitori che cercano ulteriori informazioni, Cellectis ha fornito dettagli di contatto per richieste di media e relazioni con gli investitori. Questa divulgazione regolare aiuta a mantenere la trasparenza e tiene informati gli azionisti sulla struttura del capitale dell'azienda.

Cellectis (CLLS) ha publicado su actualización mensual sobre el capital social y los derechos de voto al 31 de agosto de 2024. La empresa reportó un total de 100,093,635 acciones en el capital y 88,029,440 derechos de voto. Esta información se divulga de acuerdo con el Artículo 223-16 del Reglamento General de la autoridad de los mercados financieros franceses. Cellectis está listada en el mercado Euronext Growth bajo el código ISIN FR0010425595.

Para los inversores que buscan más información, Cellectis ha proporcionado detalles de contacto para consultas de medios y relaciones con inversores. Esta divulgación regular ayuda a mantener la transparencia y mantiene informados a los accionistas sobre la estructura del capital de la empresa.

Cellectis (CLLS)는 2024년 8월 31일 기준으로 자본금 및 의결권에 대한 월간 보고서를 발표했습니다. 이 회사는 자본금으로 100,093,635 주88,029,440 의결권을 보고했습니다. 이 정보는 프랑스 금융 시장 당국의 일반 규정 제223-16 조에 따라 공개됩니다. Cellectis는 ISIN 코드 FR0010425595로 Euronext Growth 시장에 상장되어 있습니다.

추가 정보를 원하는 투자자를 위해 Cellectis는 언론 및 투자자 관계 문의를 위한 연락처 정보를 제공했습니다. 이 정기적인 공시는 투명성을 유지하고 주주들에게 회사의 자본 구조에 대한 정보를 제공합니다.

Cellectis (CLLS) a publié sa mise à jour mensuelle sur le capital social et les droits de vote au 31 août 2024. La société a rapporté un total de 100 093 635 actions dans le capital et 88 029 440 droits de vote. Ces informations sont divulguées conformément à l'Article 223-16 du Règlement Général de l'autorité des marchés financiers français. Cellectis est cotée sur le marché Euronext Growth sous le code ISIN FR0010425595.

Pour les investisseurs souhaitant obtenir davantage d'informations, Cellectis a fourni des coordonnées pour les demandes des médias et des relations investisseurs. Cette divulgation régulière contribue à maintenir la transparence et à tenir les actionnaires informés sur la structure du capital de la société.

Cellectis (CLLS) hat sein monatliches Update zu Eigenkapital und Stimmrechten zum 31. August 2024 veröffentlicht. Das Unternehmen berichtete von insgesamt 100.093.635 Aktien im Kapital und 88.029.440 Stimmrechten. Diese Informationen werden gemäß Artikel 223-16 der Allgemeinen Vorschriften der französischen Finanzmarktaufsicht offengelegt. Cellectis ist am Euronext Growth Markt unter der ISIN-Nummer FR0010425595 gelistet.

Für Investoren, die weitere Informationen suchen, hat Cellectis Kontaktdaten für Medien- und Investor Relations-Anfragen bereitgestellt. Diese regelmäßige Offenlegung trägt dazu bei, Transparenz zu schaffen und die Aktionäre über die Kapitalstruktur des Unternehmens zu informieren.

Positive
  • Transparency in reporting share capital and voting rights
  • Compliance with French financial market regulations
Negative
  • None.

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, Sept. 04, 2024 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

DateTotal number of shares
in the capital
Total number of voting rights
08/31/2024100,093,63588,029,440

For further information on Cellectis, please contact:     

Media contact:       

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contacts:       

Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980, investors@cellectis.com

 

Attachment


FAQ

How many shares does Cellectis (CLLS) have as of August 31, 2024?

As of August 31, 2024, Cellectis (CLLS) reported a total of 100,093,635 shares in its capital.

What is the total number of voting rights for Cellectis (CLLS) as of August 31, 2024?

Cellectis (CLLS) reported 88,029,440 total voting rights as of August 31, 2024.

On which market is Cellectis (CLLS) listed?

Cellectis (CLLS) is listed on the Euronext Growth market.

What is the ISIN code for Cellectis (CLLS) stock?

The ISIN code for Cellectis (CLLS) stock is FR0010425595.

Cellectis S.A. American Depositary Shares

NASDAQ:CLLS

CLLS Rankings

CLLS Latest News

CLLS Stock Data

240.22M
72.09M
9.39%
14.77%
0.44%
Biotechnology
Healthcare
Link
United States of America
Paris